RGNX - Regenxbio - Stock Price & Dividends

REGENXBIO Inc. is a clinical-stage biotechnology company that specializes in developing innovative gene therapies to treat genetic defects. The company's proprietary NAV Technology Platform, a cutting-edge adeno-associated virus gene delivery platform, serves as the foundation for its product candidates.

The company's pipeline is robust, with several promising products in various stages of development. ABBV-RGX-314, for instance, is being developed to treat wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases. RGX-202, currently in Phase I/II clinical trial, aims to address Duchenne muscular dystrophy. Additionally, REGENXBIO is working on RGX-121, which has reached Phase III clinical trial for the treatment of mucopolysaccharidosis type II, a rare genetic disorder.

Other notable pipeline products include RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-381 for the ocular manifestations of CLN2 disease. By leveraging its NAV Technology Platform, REGENXBIO is poised to make a significant impact in the gene therapy space.

Beyond its internal product development, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies, further expanding its reach and potential. The company has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States, demonstrating its commitment to global partnerships and innovation.

Founded in 2008, REGENXBIO is headquartered in Rockville, Maryland, and is dedicated to advancing gene therapies to improve human health. For more information, visit the company's website at https://www.regenxbio.com.